Medical
Stay up-to-date on the latest medical cannabis research, news, and information with Business of Cannabis. Learn about new treatments, laws, and more.
Medical · page 2
- Cultivation
Why Pharmaceutical Standards Matter More Than Cannabis Branding
James Duckenfield, CEO of Glass Pharms®, dives into the responsibilities behind a medical cannabis brand and why pharmaceutical standards should matter more than marketing.
- Medical Cannabis
Germany to Soften Cannabis Insurance Reforms as Exilby Lobbying Row Escalates
Germany’s coalition government has retreated further on its controversial medical cannabis reimbursement reforms as it faces mounting questions over how and why the law came to be.
- Pharmaceutical
Ireland’s Dunbar Pharma Expands UK Dronabinol Range with Oral Spray
Irish active-ingredient manufacturer Dunbar Pharmaceuticals has launched the UK’s first plant-derived dronabinol oral spray, extending a pharma-grade THC line that reached specialist prescribers in capsule form in August.
- Medical Cannabis
Medical Cannabis Pioneer Bedrocan Fights to Avoid Bankruptcy in Home Market
Bedrocan, the Dutch medical cannabis stalwart thousands of patients rely on for their prescriptions, is now fighting to avoid collapse.
- Medical Cannabis
Overdue ACMD Report Gets New Deadline as Industry Weighs In
By Ben Stevens, with additional reporting by Nicole Farah, Managing Director of Americana Communications.
- Cultivation
France’s PGP Farmer Selects 5 Cannabis Strains for Future French Production as Market Nears Rollout
PGP Farmer, the French biotech building the country’s first EU-GMP medical cannabis production site, has narrowed a 30-variety Dutch phenotyping trial to five elite cultivars, laying the agronomic groundwork for its 9-hectare Dordogne facility as France closes on the reforms needed for full medical cannabis rollout.
- Medical Cannabis
UK Medical Cannabis Under Review: Where is the ACMD Report?
Pressure is piling on the UK’s Advisory Council on the Misuse of Drugs (ACMD) to publish its highly anticipated review of the country’s medical cannabis framework.
- Cultivation
Are We Underestimating the Pharmaceutical Potential of the Cannabis Plant?
James Duckenfield, CEO of Glass Pharms®, explains why we may be underestimating the pharmaceutical potential of cannabis, and how research, formulation and more controlled delivery could help realise it.
- Cultivation
Inside Northern Leaf’s Remarkable Turnaround: From Brink of Collapse to £8m Cultivator
Northern Leaf, the Jersey-based medical cannabis cultivator, looked all but certain to follow in the footsteps of Curaleaf, Aurora and Tilray to become the British Isles’ very own international cannabis superstar.
- Clinical Research
The Company That Wants to Make the Endocannabinoid System as Measurable as Blood Sugar
Dr Stefan Broselid, Founder and Scientific Lead of ECS Restore, has filed a patent application for a non-cannabinoid formulation designed to treat dysfunction in the endocannabinoid system (ECS), moving his research from scientific hypothesis towards a meaningful commercial proposition.
- International Regulation
Australia’s Medical Cannabis Reforms to Target ‘Closed Loop’ Prescribing
Australia’s ongoing efforts to restrict its medical cannabis market, now the largest outside North America, are now taking aim at the special access scheme (SAS) framework on which the country’s hundreds of thousands of annual prescriptions are based.
- US & Canada
DEA Makes Its Final Case for Cannabis Rescheduling as Full Hearing Transcripts Published
As Chief Administrative Law Judge Derek Julius weighs his recommendation on moving cannabis to Schedule III, the DEA’s own closing brief attacks nearly every witness who opposed it — bar one scientist inside its own ranks.
